A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naive NSCLC patients with EGFR mutationY-K. Shi, J. Zhou,Y. Zhao, B. Zhu, L. Zhang,X. Li, J. Fang, J. Shi, Z. Zhuang,S. Yang,D. Wang, H. Yu, L. Zhang, R. Zheng, M. Greco, T. Wang, F. MoANNALS OF ONCOLOGY（2022）引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
